使用SCH 56592治疗小鼠镰刀菌病。
Treatment of murine fusariosis with SCH 56592.
作者信息
Lozano-Chiu M, Arikan S, Paetznick V L, Anaissie E J, Loebenberg D, Rex J H
机构信息
Department of Internal Medicine, University of Texas Medical School, Houston 77030, USA.
出版信息
Antimicrob Agents Chemother. 1999 Mar;43(3):589-91. doi: 10.1128/AAC.43.3.589.
Abstract
Doses of 10 to 100 mg of the azole antifungal agent SCH 5692/kg of body weight/day were studied in immunocompetent mice as therapy for systemic infection by Fusarium solani. Treatment was begun 1 h after intravenous infection and continued daily for 4 or 13 doses. Prolongation of survival and organ clearance were dependent on both the dose and the duration of SCH 56592 therapy, with the best results seen at 50 and 100 mg/kg/day. The results at the highest doses of SCH 56592 used (50 or 100 mg/kg/day) were comparable to those obtained with amphotericin B at 1 mg/kg/day. SCH 56592 has potential for therapy of systemic infections caused by F. solani.
摘要
在免疫功能正常的小鼠中，研究了唑类抗真菌剂SCH 5692以10至100毫克/千克体重/天的剂量作为茄病镰刀菌引起的全身感染的治疗方法。在静脉感染后1小时开始治疗，并每天持续给药4或13次。生存时间的延长和器官内病菌清除情况取决于SCH 56592治疗的剂量和持续时间，在50和100毫克/千克/天的剂量下效果最佳。所使用的SCH 56592最高剂量（50或100毫克/千克/天）的结果与两性霉素B以1毫克/千克/天给药所获得的结果相当。SCH 56592有治疗茄病镰刀菌引起的全身感染的潜力。
相似文献
1
Treatment of murine fusariosis with SCH 56592.使用SCH 56592治疗小鼠镰刀菌病。
Antimicrob Agents Chemother. 1999 Mar;43(3):589-91. doi: 10.1128/AAC.43.3.589.
2
Combined therapy in treatment of murine infection by Fusarium solani.联合疗法治疗茄病镰刀菌引起的小鼠感染
J Antimicrob Chemother. 2008 Sep;62(3):543-6. doi: 10.1093/jac/dkn215. Epub 2008 May 20.
3
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.泊沙康唑治疗和预防茄病镰刀菌的疗效。
Antimicrob Agents Chemother. 2010 Mar;54(3):1055-9. doi: 10.1128/AAC.01445-09. Epub 2010 Jan 11.
4
Evaluation of antifungal therapy in a neutropenic murine model of Neoscytalidium dimidiatum infection.评价两性霉素 B 治疗中间型新孢子虫感染中性粒细胞减少症小鼠模型的效果。
Int J Antimicrob Agents. 2010 Feb;35(2):152-5. doi: 10.1016/j.ijantimicag.2009.09.028. Epub 2009 Dec 14.
5
Treatment of murine Fusarium verticillioides infection with liposomal amphotericin B plus terbinafine.脂质体两性霉素 B 联合特比萘芬治疗小鼠串珠镰刀菌感染。
Int J Antimicrob Agents. 2011 Jan;37(1):58-61. doi: 10.1016/j.ijantimicag.2010.08.008. Epub 2010 Oct 14.
6
Posaconazole efficacy in a murine disseminated infection caused by Paecilomyces lilacinus.泊沙康唑对淡紫拟青霉引起的小鼠播散性感染的疗效。
J Antimicrob Chemother. 2009 Feb;63(2):361-4. doi: 10.1093/jac/dkn497. Epub 2008 Dec 2.
7
Comparison of antifungal treatments for murine fusariosis.小鼠镰刀菌病抗真菌治疗的比较。
J Antimicrob Chemother. 2006 Nov;58(5):973-9. doi: 10.1093/jac/dkl378. Epub 2006 Sep 14.
8
Treating disseminated fusariosis: amphotericin B, voriconazole or both?治疗播散性镰刀菌病：两性霉素B、伏立康唑还是两者联用？
Mycoses. 2007 May;50(3):227-31. doi: 10.1111/j.1439-0507.2006.01346.x.
9
Comparative efficacies of amphotericin B, triazoles, and combination of both as experimental therapy for murine trichosporonosis.两性霉素B、三唑类药物以及两者联合作为小鼠毛孢子菌病实验性治疗方法的比较疗效
Antimicrob Agents Chemother. 1994 Nov;38(11):2541-4. doi: 10.1128/AAC.38.11.2541.
10
Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice.一种新型三唑类抗真菌药物（先灵葆雅56592）与伊曲康唑和两性霉素B治疗免疫功能正常小鼠组织胞浆菌病的比较。
Antimicrob Agents Chemother. 1999 Feb;43(2):322-8. doi: 10.1128/AAC.43.2.322.
引用本文的文献
1
Posaconazole: An Update of Its Clinical Use.泊沙康唑：临床应用最新进展
Pharmacy (Basel). 2015 Oct 21;3(4):210-268. doi: 10.3390/pharmacy3040210.
2
Murine model of disseminated fusariosis: evaluation of the fungal burden by traditional CFU and quantitative PCR.播散性镰刀菌病的鼠模型：传统 CFU 和定量 PCR 评估真菌负担。
Mycopathologia. 2013 Oct;176(3-4):219-24. doi: 10.1007/s11046-013-9687-3. Epub 2013 Aug 13.
3
Fusariosis, a complex infection caused by a high diversity of fungal species refractory to treatment. Fusariosis，一种由多种真菌物种引起的复杂感染，对治疗有抗药性。
Eur J Clin Microbiol Infect Dis. 2013 Dec;32(12):1491-500. doi: 10.1007/s10096-013-1924-7. Epub 2013 Aug 11.
4
Conazoles.康唑类药物。
Molecules. 2010 Jun 9;15(6):4129-88. doi: 10.3390/molecules15064129.
5
Pharmacokinetic/pharmacodynamic profile of posaconazole.泊沙康唑的药代动力学/药效学特征。
Clin Pharmacokinet. 2010 Jun;49(6):379-96. doi: 10.2165/11319340-000000000-00000.
6
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.泊沙康唑治疗和预防茄病镰刀菌的疗效。
Antimicrob Agents Chemother. 2010 Mar;54(3):1055-9. doi: 10.1128/AAC.01445-09. Epub 2010 Jan 11.
7
Efficacy of triazoles in a murine disseminated infection by Candida krusei.三唑类药物对克鲁斯念珠菌所致小鼠播散性感染的疗效
Antimicrob Agents Chemother. 2009 Aug;53(8):3585-8. doi: 10.1128/AAC.00293-09. Epub 2009 May 26.
8
Posaconazole.泊沙康唑
Drugs. 2005;65(11):1553-67; discussion 1568-9. doi: 10.2165/00003495-200565110-00007.
9
Antifungal activities of posaconazole and granulocyte-macrophage colony-stimulating factor ex vivo and in mice with disseminated infection due to Scedosporium prolificans.泊沙康唑与粒细胞巨噬细胞集落刺激因子对多育赛多孢菌所致播散性感染小鼠的体内外抗真菌活性
Antimicrob Agents Chemother. 2004 Oct;48(10):3801-5. doi: 10.1128/AAC.48.10.3801-3805.2004.
10
Concurrent Fusarium chlamydosporum and Microsphaeropsis arundinis infections in a cat.一只猫同时感染了厚垣镰刀菌和芦苇拟盘多毛孢菌。
J Feline Med Surg. 2004 Aug;6(4):271-7. doi: 10.1016/j.jfms.2003.08.006.
本文引用的文献
1
Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp.SCH 56592与氟康唑和伊曲康唑对念珠菌属的活性比较
Antimicrob Agents Chemother. 1997 Oct;41(10):2310-1. doi: 10.1128/AAC.41.10.2310.
2
Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis.三唑类药物SCH 56592对播散性小鼠球孢子菌病的活性。
Antimicrob Agents Chemother. 1997 Jul;41(7):1558-61. doi: 10.1128/AAC.41.7.1558.
3
Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus.SCH-56592在侵袭性曲霉病的暂时中性粒细胞减少小鼠模型中对一株伊曲康唑敏感和一株伊曲康唑耐药的烟曲霉分离株的疗效。
Antimicrob Agents Chemother. 1997 Jul;41(7):1504-7. doi: 10.1128/AAC.41.7.1504.
4
In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains.临床和环境中镰刀菌属菌株的体外抗真菌药敏性。
J Antimicrob Chemother. 1997 Feb;39(2):163-7. doi: 10.1093/jac/39.2.163.
5
Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae.一种新型三唑类药物Sch 56592的活性，与其他四种抗真菌药物针对念珠菌属和酿酒酵母临床分离株的活性比较。
Antimicrob Agents Chemother. 1997 Feb;41(2):233-5. doi: 10.1128/AAC.41.2.233.
6
In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis.SCH 56592对皮炎芽生菌的体外和体内活性
Antimicrob Agents Chemother. 1996 May;40(5):1314-6. doi: 10.1128/AAC.40.5.1314.
7
Opportunistic fusarial infections in humans.人类的机会性镰刀菌感染。
Eur J Clin Microbiol Infect Dis. 1995 Sep;14(9):741-54. doi: 10.1007/BF01690988.
8
Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management.免疫功能低下患者中的新兴真菌病原体：分类、诊断与管理。
Clin Infect Dis. 1993 Nov;17 Suppl 2:S487-91. doi: 10.1093/clinids/17.supplement_2.s487.
9
In vitro sensitivity of medically significant Fusarium species to various antimycotics.具有医学意义的镰刀菌属菌种对多种抗真菌药物的体外敏感性
Chemotherapy. 1994 Jul-Aug;40(4):239-44. doi: 10.1159/000239199.
10
Fusarium infections in immunocompromised patients: case reports and literature review.免疫功能低下患者的镰刀菌感染：病例报告与文献综述
Eur J Clin Microbiol Infect Dis. 1994 Feb;13(2):152-61. doi: 10.1007/BF01982190.
Zotero 插件